22,135,656
Vote Records
28,570
Companies
12,092
Funds
3,981
Managers

Home › Companies › ZENTALIS PHARMACEUTICALS INC. › 2024-2025

ZENTALIS PHARMACEUTICALS INC. 2024-2025 Proxy Voting Records

Download data (CSV): ballot items · votes by manager · column guide.

Compiled from SEC Form N-PX filings and ZENTALIS PHARMACEUTICALS INC.’s Form 8-K, filed June 18, 2025 (Item 5.07 on EDGAR). Page generated November 20, 2026.

  • 5Ballot items
  • 125Asset managers, any item
  • 730Fund votes
  • June 17, 2025Meeting date

Results at a glance

Meeting of June 17, 2025: 5 items on ZENTALIS PHARMACEUTICALS INC.’s Form 8-K, filed June 18, 2025: 1 approved · 4 passed (calculated).

Dissent

Significant dissent: 2 directors (34.7%, 22.1% against); 1 say-on-pay vote (62.9% support).

Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Explore ZENTALIS PHARMACEUTICALS INC. in the interactive database Compare manager voting policies

Official 2024-2025 meeting results reported by ZENTALIS PHARMACEUTICALS INC.

These tallies are ZENTALIS PHARMACEUTICALS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 18, 2025 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

ZENTALIS PHARMACEUTICALS INC. — official shareholder meeting results, meeting held June 17, 2025
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: Scott Myers 43,014,172---- 3,948,49111,249,440 92%Passed (calculated)—
Elect Director: Karan Takhar 30,655,734---- 16,306,92911,249,440 65%Passed (calculated)—
Elect Director: Luke Walker, M.D. 36,599,420---- 10,363,24311,249,440 78%Passed (calculated)—
2. Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025 58,100,23010,761101,112 --0 99.9%Passed (calculated)—
3. Approval, on an advisory (non-binding) basis, the compensation of the Company's named executive officers 29,474,72017,374,784113,159 --11,249,440 63%Approved—

Source: ZENTALIS PHARMACEUTICALS INC., Form 8-K, filed with the SEC on June 18, 2025 — read the filing on EDGAR.

How asset managers voted at the ZENTALIS PHARMACEUTICALS INC. 2024-2025 meeting

125 asset managers disclosed a vote on at least one ZENTALIS PHARMACEUTICALS INC. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.

Elect Director: Karan Takhar

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 3 wordings of this item as funds reported it.

65% Majority: yes · of votes cast

FOR 65%WITHHELD
FOR: 30,655,734WITHHELD: 16,306,929
Details: description as filed, official tally, votes by 45 asset managers

Description as filed by funds: Election of Class II Directors to serve until the 2028 Annual Meeting of Stockholders, and until their respective successors shall have been duly elected and qualified, subject to their earlier death, resignation or removal: Karan Takhar

ZENTALIS PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Karan Takhar”): 30,655,734 for, 16,306,929 withheld, per its Form 8-K filed June 18, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 65% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 45 asset managers below reported 5,820,650 for, 3,842,711 withheld, 109,697 abstained.

FORWITHHOLD
FOR: 5,820,650ABSTAIN: 109,697WITHHOLD: 3,842,711
Largest asset managers voting on “Election of Class II Directors to serve until the 2028 Annual Meeting of Stockholders, and until their respect” at ZENTALIS PHARMACEUTICALS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard3,222,7050 00For
BlackRock1,430,8190 00For
Fidelity00 01,352,554Withhold
PRIMECAP Odyssey Funds861,4000 00For
Federated Hermes00 0729,178Withhold
Charles Schwab00 0490,062Withhold
TIAA00 0472,207Withhold
Equitable92,7700 0109,538Mixed
BRIDGEWAY FUNDS INC00 0152,300Withhold
Invesco00 0123,843Withhold
QUANTITATIVE MASTER SERIES LLC95,3100 00For
Thrivent00 068,827Withhold
Nationwide14,3420 053,278Mixed
ETF Series Solutions00 67,4010Abstain
Goldman Sachs00 052,534Withhold
Lincoln Financial40,7000 06,070Mixed
ETFis Series Trust I00 035,939Withhold
Global X00 034,506Withhold
Pacific Life30,4260 00For
AIG/SunAmerica00 029,192Withhold
Bridge Builder Trust25,4840 00For
John Hancock00 23,1390Abstain
Northern Trust00 022,398Withhold
Russell Investments00 020,716Withhold
Voya00 017,282Withhold

Showing the 25 largest of 45 asset managers. All 45 are in the interactive database (link above).

Elect Director: Luke Walker, M.D.

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 3 wordings of this item as funds reported it.

78% Majority: yes · of votes cast

FOR 78%WITHHELD
FOR: 36,599,420WITHHELD: 10,363,243
Details: description as filed, official tally, votes by 45 asset managers

Description as filed by funds: Election of Class II Directors to serve until the 2028 Annual Meeting of Stockholders, and until their respective successors shall have been duly elected and qualified, subject to their earlier death, resignation or removal: Luke Walker, M.D.

ZENTALIS PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Luke Walker, M.D.”): 36,599,420 for, 10,363,243 withheld, per its Form 8-K filed June 18, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 78% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 45 asset managers below reported 8,440,734 for, 1,225,957 withheld, 106,367 abstained.

FOR
FOR: 8,440,734ABSTAIN: 106,367WITHHOLD: 1,225,957
Largest asset managers voting on “Election of Class II Directors to serve until the 2028 Annual Meeting of Stockholders, and until their respect” at ZENTALIS PHARMACEUTICALS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard3,222,7050 00For
BlackRock1,430,8190 00For
Fidelity1,183,3770 0169,177Mixed
PRIMECAP Odyssey Funds861,4000 00For
Federated Hermes729,1780 00For
Charles Schwab490,0620 00For
TIAA00 0472,207Withhold
Equitable92,7700 0109,538Mixed
BRIDGEWAY FUNDS INC00 0152,300Withhold
Invesco123,8430 00For
QUANTITATIVE MASTER SERIES LLC95,3100 00For
Thrivent00 068,827Withhold
Nationwide16,2170 051,403Mixed
ETF Series Solutions00 67,4010Abstain
Goldman Sachs00 052,534Withhold
Lincoln Financial40,7000 06,070Mixed
ETFis Series Trust I00 035,939Withhold
Global X34,5060 00For
Pacific Life30,4260 00For
AIG/SunAmerica00 029,192Withhold
Bridge Builder Trust25,4840 00For
John Hancock00 23,1390Abstain
Northern Trust22,3980 00For
Russell Investments20,7160 00For
Voya00 017,282Withhold

Showing the 25 largest of 45 asset managers. All 45 are in the interactive database (link above).

Elect Director: Scott Myers

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 3 wordings of this item as funds reported it.

92% Majority: yes · of votes cast

FOR 92%
FOR: 43,014,172WITHHELD: 3,948,491
Details: description as filed, official tally, votes by 45 asset managers

Description as filed by funds: Election of Class II Directors to serve until the 2028 Annual Meeting of Stockholders, and until their respective successors shall have been duly elected and qualified, subject to their earlier death, resignation or removal: Scott Myers

ZENTALIS PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Scott Myers”): 43,014,172 for, 3,948,491 withheld, per its Form 8-K filed June 18, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 92% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 45 asset managers below reported 8,317,009 for, 1,448,534 withheld, 7,515 abstained.

FORWITHHOLD
FOR: 8,317,009ABSTAIN: 7,515WITHHOLD: 1,448,534
Largest asset managers voting on “Election of Class II Directors to serve until the 2028 Annual Meeting of Stockholders, and until their respect” at ZENTALIS PHARMACEUTICALS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard3,222,7050 00For
BlackRock1,430,8190 00For
Fidelity1,183,3770 0169,177Mixed
PRIMECAP Odyssey Funds861,4000 00For
Federated Hermes00 0729,178Withhold
Charles Schwab00 0490,062Withhold
TIAA472,2070 00For
Equitable202,3080 00For
BRIDGEWAY FUNDS INC152,3000 00For
Invesco123,8430 00For
QUANTITATIVE MASTER SERIES LLC95,3100 00For
Thrivent68,8270 00For
Nationwide67,6200 00For
ETF Series Solutions67,4010 00For
Goldman Sachs00 052,534Withhold
Lincoln Financial40,7000 06,070Mixed
ETFis Series Trust I35,9390 00For
Global X34,5060 00For
Pacific Life30,4260 00For
AIG/SunAmerica29,1920 00For
Bridge Builder Trust25,4840 00For
John Hancock23,1390 00For
Northern Trust22,3980 00For
Russell Investments20,7160 00For
Voya17,2820 00For

Showing the 25 largest of 45 asset managers. All 45 are in the interactive database (link above).

Approval, on an advisory (non-binding) basis, the compensation of the Company's named executive officers

Official resultFund totals may overlapSECTION 14A SAY-ON-PAY VOTESReported outcome: Approved

Combines 4 wordings of this item as funds reported it.

63% Approved · of votes cast

FOR 63%AGAINST
FOR: 29,474,720AGAINST: 17,374,784

Prior year: 59.4% for (June 21, 2024 meeting) ▲ 3.5 pts

Details: description as filed, official tally, votes by 125 asset managers

Description as filed by funds: TO APPROVE, ON AN ADVISORY (NON-BINDING) BASIS, THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS.

ZENTALIS PHARMACEUTICALS INC.’s own tally for this item (“3. Approval, on an advisory (non-binding) basis, the compensation of the Company's named executive officers”): 29,474,720 for, 17,374,784 against — passed, per its Form 8-K filed June 18, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Item 3 — Approval, on an advisory (non-binding) basis, the compensation of the Company's named executive officers.”
Support: 63% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 45 asset managers voting on “TO APPROVE, ON AN ADVISORY (NON-BINDING) BASIS, THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS.” at ZENTALIS PHARMACEUTICALS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard3,222,7050 00For
BlackRock01,430,819 00Against
Fidelity01,352,554 00Against
PRIMECAP Odyssey Funds861,4000 00For
Federated Hermes0729,178 00Against
Charles Schwab0490,062 00Against
TIAA0472,207 00Against
Equitable0202,308 00Against
BRIDGEWAY FUNDS INC0152,300 00Against
Invesco0123,843 00Against
QUANTITATIVE MASTER SERIES LLC095,310 00Against
Thrivent068,827 00Against
Nationwide067,620 00Against
ETF Series Solutions067,401 00Against
Goldman Sachs052,534 00Against
Lincoln Financial40,7006,070 00Mixed
ETFis Series Trust I035,939 00Against
Global X034,506 00Against
Pacific Life030,426 00Against
AIG/SunAmerica029,192 00Against
Bridge Builder Trust025,484 00Against
John Hancock023,139 00Against
Northern Trust22,3980 00For
Russell Investments020,716 00Against
Voya017,282 00Against

Fund voting reports, all 45 managers: 4,153,897 for, 5,617,863 against, 1,298 abstained. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 96 asset managers voting on “TO APPROVE, ON AN ADVISORY (NON-BINDING) BASIS, THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS.” at ZENTALIS PHARMACEUTICALS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Matrix Capital Management Company, LP13,959,9730 00For
Opaleye Management Inc.1,910,0000 00For
BlackRock18,5111,751,641 00Against
GEODE CAPITAL MANAGEMENT, LLC01,335,969 00Against
PRIMECAP MANAGEMENT CO/CA/1,163,5200 00For
TYBOURNE CAPITAL MANAGEMENT (HK) LTD0961,486 00Against
DE Shaw0926,914 00Against
Federated Hermes0759,538 00Against
State Street688,5134,678 00For
Decheng Capital LLC00 00--
Woodline Partners LP523,5190 00For
Nuveen0507,527 00Against
Charles Schwab0490,062 00Against
5AM Venture Management, LLC490,0000 00For
Connor, Clark & Lunn Investment Management Ltd.0330,539 00Against
AQR0315,008 00Against
Renaissance0307,947 00Against
Two Sigma0244,645 00Against
Northern Trust235,83948 00For
Fidelity0179,324 00Against
MELLON INVESTMENTS Corp0178,566 00Against
BRIDGEWAY CAPITAL MANAGEMENT, LLC0152,300 00Against
Invesco0143,208 00Against
Maryland State Retirement & Pension System0113,203 00Against
AllianceBernstein0109,538 00Against

Institutional-manager reports, all 96 managers: 19,300,781 for, 9,914,681 against, 4,000 not voted, 565,435 unknown. Showing the 25 largest; every one is in the interactive database (link above).

Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for…

Calculated outcomeAUDIT-RELATEDPassed (calculated)

99.9% Majority: yes · of votes cast

FOR 99.9%
FOR: 58,100,230AGAINST: 10,761

Prior year: 100.0% for (June 21, 2024 meeting) unchanged

Details: description as filed, official tally, votes by 45 asset managers

Description as filed by funds: TO RATIFY THE APPOINTMENT OF ERNST & YOUNG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2025.

ZENTALIS PHARMACEUTICALS INC.’s own tally for this item (“2. Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025”): 58,100,230 for, 10,761 against, per its Form 8-K filed June 18, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 45 asset managers below reported 9,771,760 for, 1,298 abstained.

FOR
FOR: 9,771,760ABSTAIN: 1,298
Largest asset managers voting on “TO RATIFY THE APPOINTMENT OF ERNST & YOUNG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FI” at ZENTALIS PHARMACEUTICALS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard3,222,7050 00For
BlackRock1,430,8190 00For
Fidelity1,352,5540 00For
PRIMECAP Odyssey Funds861,4000 00For
Federated Hermes729,1780 00For
Charles Schwab490,0620 00For
TIAA472,2070 00For
Equitable202,3080 00For
BRIDGEWAY FUNDS INC152,3000 00For
Invesco123,8430 00For
QUANTITATIVE MASTER SERIES LLC95,3100 00For
Thrivent68,8270 00For
Nationwide67,6200 00For
ETF Series Solutions67,4010 00For
Goldman Sachs52,5340 00For
Lincoln Financial46,7700 00For
ETFis Series Trust I35,9390 00For
Global X34,5060 00For
Pacific Life30,4260 00For
AIG/SunAmerica29,1920 00For
Bridge Builder Trust25,4840 00For
John Hancock23,1390 00For
Northern Trust22,3980 00For
Russell Investments20,7160 00For
Voya17,2820 00For

Showing the 25 largest of 45 asset managers. All 45 are in the interactive database (link above).

Largest ZENTALIS PHARMACEUTICALS INC. shareholders voting in 2024-2025

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 71,951,934 shares outstanding at the time of that meeting.

Fund voting reports: top ZENTALIS PHARMACEUTICALS INC. shareholders by shares voted on “TO APPROVE, ON AN ADVISORY (NON-BINDING) BASIS, THE COMPENSATION OF OUR NAMED EXECUTIVE…”, 2024-2025
#Asset manager % of shares outstanding
1Vanguard 4.48%
2BlackRock 1.99%
3Fidelity 1.88%
4PRIMECAP Odyssey Funds 1.20%
5Federated Hermes 1.01%
6Charles Schwab 0.68%
7TIAA 0.66%
8Equitable 0.28%
9BRIDGEWAY FUNDS INC 0.21%
10Invesco 0.17%
Institutional-manager reports: top ZENTALIS PHARMACEUTICALS INC. shareholders by shares voted on “TO APPROVE, ON AN ADVISORY (NON-BINDING) BASIS, THE COMPENSATION OF OUR NAMED EXECUTIVE…”, 2024-2025
#Asset manager % of shares outstanding
1Matrix Capital Management Company, LP 19.40%
2Opaleye Management Inc. 2.65%
3BlackRock 2.46%
4GEODE CAPITAL MANAGEMENT, LLC 1.86%
5PRIMECAP MANAGEMENT CO/CA/ 1.62%
6TYBOURNE CAPITAL MANAGEMENT (HK) LTD 1.34%
7DE Shaw 1.29%
8Federated Hermes 1.06%
9State Street 0.96%
10Decheng Capital LLC 0.79%

Reported ZENTALIS PHARMACEUTICALS INC. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.

ZENTALIS PHARMACEUTICALS INC. holdings and ownership disclosed for the 2024-2025 proxy season, with each row’s source and date
HolderShares % outstandingSource, as of
Matrix Capital Management Master Fund, LP13,959,973 19.40%Proxy statement (DEF 14A), proxy filed April 30, 2025
WALTERS GROUP13,509,973 18.78%Schedule 13G, filed January 5, 2026
William T. Walters7,050,000 9.80%Proxy statement (DEF 14A), proxy filed April 30, 2025
Andrew J. Schwab4,838,571 6.72%Schedule 13G, filed December 30, 2025
Eventide Asset Management, LLC4,475,054 6.22%Proxy statement (DEF 14A), proxy filed April 30, 2025
BlackRock4,229,497 5.88%Form 13F, quarter ended March 31, 2025
Barclays PLC3,841,449 5.34%Schedule 13G, filed November 12, 2025
Squadron Master Fund LP3,676,900 5.11%Schedule 13G, filed March 3, 2026
Vanguard Group3,260,612 4.53%Form 13F, quarter ended March 31, 2025
Millennium Management3,069,514 4.27%Form 13F, quarter ended March 31, 2025

Percentages above are of 71,951,934 shares outstanding, as reported by ZENTALIS PHARMACEUTICALS INC. on its Form 10-Q dated May 12, 2025 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this meeting

At ZENTALIS PHARMACEUTICALS INC.'s shareholder meeting held June 17, 2025, in the 2024-2025 proxy season, 125 asset managers reported votes on at least one of its 5 ballot items in their SEC Form N-PX filings, covering 730 separate fund positions. On the most widely held item on that ballot — TO APPROVE, ON AN ADVISORY (NON-BINDING) BASIS, THE COMPENSATION OF OUR NAMED EXECUTIVE… — ZENTALIS PHARMACEUTICALS INC.'s filing reports the proposal as approved, with 63% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: ZENTALIS PHARMACEUTICALS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 18, 2025.

Related

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from ZENTALIS PHARMACEUTICALS INC.’s 10-Q dated May 12, 2025. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.

ZENTALIS PHARMACEUTICALS INC. proxy season coverage: 2023-2024 · 2024-2025 (this page) · 2025-2026.

Cite this page

Proxy Votes Now, “ZENTALIS PHARMACEUTICALS (ZNTL) 2025 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/zentalis-pharmaceuticals-inc/2025 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.